NEW YORK (GenomeWeb) – Myriad Genetics is hoping that data from a large randomized controlled study published last week on GeneSight will change the reimbursement prospects for the pharmacogenetic test, as well as shift the standard of care for treating depression.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.